Inherited Follicular Epithelial-Derived Thyroid Carcinomas: From Molecular Biology to Histological Correlates

被引:0
作者
José Manuel Cameselle-Teijeiro
Ozgur Mete
Sylvia L. Asa
Virginia LiVolsi
机构
[1] Clinical University Hospital,Department of Pathology, Galician Healthcare Service (SERGAS)
[2] Health Research Institute of Santiago de Compostela (IDIS),Medical Faculty
[3] University of Santiago de Compostela,Department of Pathology and Endocrine Oncology Site
[4] University Health Network,Department of Laboratory Medicine and Pathobiology, Faculty of Medicine
[5] University of Toronto,Department of Pathology
[6] University Hospitals Cleveland Medical Center,Department of Pathology and Laboratory Medicine
[7] Case Western Reserve University,undefined
[8] Perelmann School of Medicine of the University of Pennsylvania,undefined
来源
Endocrine Pathology | 2021年 / 32卷
关键词
Thyroid cancer; Familial non-medullary thyroid carcinoma; Cribriform-morular thyroid carcinoma; FAP; Cowden syndrome; PTEN-hamartoma tumor syndrome; DICER1 syndrome; Carney complex; Wermer syndrome;
D O I
暂无
中图分类号
学科分类号
摘要
Cancer derived from thyroid follicular epithelial cells is common; it represents the most common endocrine malignancy. The molecular features of sporadic tumors have been clarified in the past decade. However the incidence of familial disease has not been emphasized and is often overlooked in routine practice. A careful clinical documentation of family history or familial syndromes that can be associated with thyroid disease can help identify germline susceptibility-driven thyroid neoplasia. In this review, we summarize a large body of information about both syndromic and non-syndromic familial thyroid carcinomas. A significant number of patients with inherited non-medullary thyroid carcinomas manifest disease that appears to be sporadic disease even in some syndromic cases. The cytomorphology of the tumor(s), molecular immunohistochemistry, the findings in the non-tumorous thyroid parenchyma and other associated lesions may provide insight into the underlying syndromic disorder. However, the increasing evidence of familial predisposition to non-syndromic thyroid cancers is raising questions about the importance of genetics and epigenetics. What appears to be “sporadic” is becoming less often truly so and more often an opportunity to identify and understand novel genetic variants that underlie tumorigenesis. Pathologists must be aware of the unusual morphologic features that should prompt germline screening. Therefore, recognition of harbingers of specific germline susceptibility syndromes can assist in providing information to facilitate early detection to prevent aggressive disease.
引用
收藏
页码:77 / 101
页数:24
相关论文
共 1837 条
[1]  
Maxwell EL(2004)Familial non-medullary thyroid cancer: a matched-case control study Laryngoscope. 114 2182-2186
[2]  
Hall FT(2006)On the prevalence of familial nonmedullary thyroid cancer in multiply affected kindreds Thyroid. 16 181-186
[3]  
Freeman JL(2007)An evidence-based approach to familial nonmedullary thyroid cancer: screening, clinical management, and follow-up World J Surg. 31 924-933
[4]  
Charkes ND(2009)Biological behavior and prognosis of familial papillary thyroid carcinoma Surgery. 145 100-105
[5]  
Sippel RS(2011)Prevalence, clinicopathologic features, and somatic genetic mutation profile in familial versus sporadic nonmedullary thyroid cancer Thyroid. 21 367-371
[6]  
Caron NR(2011)Clinical characteristics and outcome of familial nonmedullary thyroid cancer: a retrospective controlled study Thyroid. 21 43-48
[7]  
Clark OH(2012)The long-term outcomes of the second generation of familial nonmedullary thyroid carcinoma are more aggressive than sporadic cases Thyroid. 22 356-362
[8]  
Ito Y(2013)Familial nonmedullary thyroid carcinoma Thyroid. 23 1049-1056
[9]  
Kakudo K(2020)Should Total Thyroidectomy Be Recommended for Patients with Familial Non-medullary Thyroid Cancer? World J Surg. 44 3022-3027
[10]  
Hirokawa M(1955)Carcinoma of the thyroid and other diseases of the thyroid in identical twins AMA Arch Surg. 70 923-928